Hyperinsulinism: Clinical Trials

14 trials for Hyperinsulinism, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 terminated. 14 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 114Terminated 14
Phase 25Terminated 5

Follow Hyperinsulinism: new trials by email Literature Review of Hyperinsulinism trials Research Report on Hyperinsulinism

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Diazoxide Suppression Test P&F Study
Diazoxide, 3 mg/kg per dose - Insulin Resistance, Hyperinsulinemia
Phase 1TerminatedColumbia University12024-10-232026-08-07
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
ALN-KHK, Placebo - Type 2 Diabetes Mellitus (T2DM)
Phase 1 / Phase 2TerminatedAlnylam Pharmaceuticals492023-03-102025-05-07
Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma
Roflumilast, Placebo - Asthma
Phase 1TerminatedUniversity of California, Davis52019-01-212023-10-24
Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.
UCMSCs, BMMSCs, Placebo - Endothelial Dysfunction, Metabolic Syndrome
Phase 1 / Phase 2TerminatedJoshua M Hare142018-04-122022-11-08
Pharmacogenomics of GLP1 Receptor Agonists
Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT) - Type 2 Diabetes
Phase 1TerminatedUniversity of Maryland, Baltimore632016-06-012025-07-01
The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome
TA-65, Placebo - Metabolic Syndrome, Insulin Resistance
Phase 1TerminatedUniversity of Connecticut132013-01-012015-05-28
Molecular Regulation of Muscle Glucose Metabolism
U100 Humulin, Exercise - Obesity, Type 2 Diabetes Mellitus
Phase 1TerminatedMayo Clinic482012-04-012017-11-27
Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)
Salsalate - Polycystic Ovary Syndrome
Phase 1TerminatedIndiana University472012-02-012017-02-10
Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates
glucagon like peptide-1, glucose control - Type 2 Diabetes
Phase 1 / Phase 2TerminatedAlbert Einstein College of Medicine202010-08-122024-02-28
Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes
Tadalafil - Type 2 Diabetes
Phase 1TerminatedVastra Gotaland Region222009-11-012020-02-12
Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
Exendin (9-39), Vehicle - Congenital Hyperinsulinism
Phase 1 / Phase 2TerminatedDiva De Leon142009-08-262020-06-01
Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome
Cinnamon Supplementation, Placebo (wheat flour) - Polycystic Ovary Syndrome, Insulin Resistance
Phase 1TerminatedPennington Biomedical Research Center82009-08-012021-08-25
Treatment of Type 2 Diabetes Mellitus by Duodenal Exclusion Associated With Omentectomy: Clinical and Hormonal Study
Duodenal exclusion plus omentectomy, Duodenal exclusion without omentectomy - Diabetes Mellitus, Type 2, Insulin Resistance
Phase 1 / Phase 2TerminatedUniversity of Campinas, Brazil62007-07-012010-07-23
Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome
Zoladex, Testosterone gel, Anastrozole Pill - Metabolic Syndrome
Phase 1TerminatedMassachusetts General Hospital662006-09-012017-04-18

Narrower conditions

Insulin Resistance (10)  ·  Diabetes Mellitus, Type 2 (7)  ·  Obesity (5)  ·  Metabolic Syndrome (3)  ·  Hypoglycemia (2)  ·  Overweight (2)  ·  Polycystic Ovary Syndrome (2)  ·  Asthma (1)  ·  Congenital Hyperinsulinism (1)  ·  Diabetes Mellitus (1)  ·  Glucose Metabolism Disorders (1)  ·  Hyperandrogenism (1)  ·  Infant, Newborn, Diseases (1)  ·  Inflammation (1)

Broader conditions

Nutritional and Metabolic Diseases (14)  ·  Glucose Metabolism Disorders (13)  ·  Metabolic Diseases (13)  ·  Endocrine System Diseases (10)  ·  Diabetes Mellitus (7)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Body Weight (5)  ·  Nutrition Disorders (5)  ·  Overnutrition (5)  ·  Signs and Symptoms (5)  ·  Overweight (3)  ·  Adnexal Diseases (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Cysts (2)

Interventions

Anastrozole (1)  ·  Diazoxide (1)  ·  Exenatide (1)  ·  Exercise (1)  ·  Flour (1)  ·  Glucagon-Like Peptide 1 (1)  ·  Glycemic Control (1)  ·  Goserelin (1)  ·  Incretins (1)  ·  Insulin (1)  ·  Insulin, Regular, Human (1)  ·  Roflumilast (1)  ·  Tadalafil (1)  ·  Testosterone (1)  ·  exendin (9-39) (1)

Sponsors

Albert Einstein College of Medicine (1)  ·  Alnylam Pharmaceuticals (1)  ·  Columbia University (1)  ·  Diva De Leon (1)  ·  Indiana University (1)  ·  Joshua M Hare (1)  ·  Massachusetts General Hospital (1)  ·  Mayo Clinic (1)  ·  Pennington Biomedical Research Center (1)  ·  University of California, Davis (1)  ·  University of Campinas, Brazil (1)  ·  University of Connecticut (1)  ·  University of Maryland, Baltimore (1)  ·  Vastra Gotaland Region (1)

Countries

United States (12)  ·  Brazil (1)  ·  Canada (1)  ·  Sweden (1)

Top investigators

Bruno Geloneze, MD, PhD (1)  ·  Daniel T Stein, MD (1)  ·  Diva D De Leon, MD MSCE (1)  ·  Frances J Hayes, MD (1)  ·  Joshua M Hare, MD (1)  ·  Joshua R Cook, MD, PhD (1)  ·  Lawrence J. Mandarino, PhD (1)  ·  Leanne Redman, PhD (1)  ·  Lori Roust, MD (1)  ·  Maria-Luz Fernandez, Ph.D. (1)  ·  Nicholas Kenyon, MD (1)  ·  Per-Anders Jansson, MD, PhD (1)

Results publications

PMID 19475464, PMID 30590569, PMID 32140727, PMID 32325487, PMID 38700326, PMID 41388232

NIH funding

R01DK061644 (1)